RenovoRx Inc (RNXT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, RenovoRx Inc (RNXT) has a cash flow conversion efficiency ratio of -0.557x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.02 Million) by net assets ($5.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RenovoRx Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
RenovoRx Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how RenovoRx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
RenovoRx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RenovoRx Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wijaya Karya Beton
JK:WTON
|
0.038x |
|
Seplat Petroleum Development Company PLC
LSE:SEPL
|
0.367x |
|
Charnic Capital Tbk PT
JK:NICK
|
0.145x |
|
Lotte Chilsung Beverage Co Ltd
KO:005305
|
0.033x |
|
Pacgold Ltd
AU:PGO
|
-0.032x |
|
Bo Lak
KO:002760
|
0.038x |
|
Enegex Ltd
AU:ENX
|
-0.061x |
|
OCA Acquisition Corp
NASDAQ:OCAX
|
-0.003x |
Annual Cash Flow Conversion Efficiency for RenovoRx Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of RenovoRx Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see RenovoRx Inc (RNXT) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.42 Million | $-10.97 Million | -2.024x | +0.68% |
| 2024-12-31 | $4.48 Million | $-9.12 Million | -2.038x | -159.59% |
| 2023-12-31 | $-3.00 Million | $-10.26 Million | 3.419x | +339.17% |
| 2022-12-31 | $6.16 Million | $-8.81 Million | -1.430x | -270.92% |
| 2021-12-31 | $15.35 Million | $-5.92 Million | -0.385x | -260.12% |
| 2020-12-31 | $-14.66 Million | $-3.53 Million | 0.241x | +110.53% |
| 2019-12-31 | $1.47 Million | $-3.35 Million | -2.287x | -- |
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded i… Read more